PTCT - PTCセラピュ―ティクス （PTC Therapeutics Inc.） PTCセラピュ―ティクスPTCTのチャート
PTCTの企業情報
| symbol | PTCT |
|---|---|
| 会社名 | PTC Therapeutics Inc （PTCセラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 PTCセラピューティックス(PTC Therapeutics Inc.)はバイオ医薬品会社である。同社はリボ核酸（RNA）生物学の専門知識を用いて医薬品の発見、開発、商品化に従事する。その製品パイプラインにはAtaluren（Translarna）、PTC596、およびRG7916が含まれる。製品候補であるatalurenは、ナンセンス変異に起因する遺伝性疾患の患者の治療用の経口投与された小分子化合物である。Atalurenは、ナンセンス突然変異（nmDMD）及びナンセンス突然変異（nmCF）に起因する嚢胞性線維症によって引き起こされるデュシェンヌ型筋ジストロフィーの治療用の臨床開発中である。PTC596は、BMI1の機能、活性及び量を減少させることによって腫瘍幹細胞集団を標的とする経口活性小分子である。RG7916は、小児発症（II型/ III型）脊髄性筋萎縮症（SMA）患者の試験であるSUNFISHと、乳児発症（I型）SMA患者における試験であるFIREFISHの2つの臨床試験における治験用経口治療薬である。 PTCセラピュ―ティクスは、米国のバイオ製薬会社。転写後制御プロセスをタ―ゲットにした経口投与の小分子薬を発見、開発する。主要製品候補は、ナンセンス突然変異として知られる遺伝子変異から発生する遺伝性疾患の治療薬「ataluren」である。他にも、神経筋疾患、腫瘍学、感染症など、複数の治療分野において、新たな治療法の開発を手掛ける。 ptc is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. while ptc’s discovery programs are directed at targets in multiple therapeutic areas, ptc is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. ptc’s internally-discovered pipeline addresses multiple therapeutic areas, including neuromuscular disorders, oncology and infectious diseases. for more information on the company, please visit our website www.ptcbio.com. |
| 本社所在地 | 100 Corporate Court South Plainfield NJ 07080 USA |
| 代表者氏名 | Michael Schmertzler マイケル・シュミッツラー |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 908-222-7000 |
| 設立年月日 | 35855 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2013年 |
| 従業員数 | 373人 |
| url | www.ptcbio.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ptct |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -19.28200 |
| 終値（lastsale） | 40.91 |
| 時価総額（marketcap） | 2054287181.63 |
| 時価総額 | 時価総額（百万ドル） 1775.128 |
| 売上高 | 売上高（百万ドル） 244.68800 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1627.892 |
| 当期純利益 | 当期純利益（百万ドル） -61.25100 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 PTC Therapeutics Inc. revenues increased 68% to $124.8M. Net loss decreased 38% to $28.8M. Revenues reflect Collaboration and grant revenue increase from $176K to $654K. Lower net loss reflects Other income net increase from $2.1M (expense) to $331K (income) Stock-based Compensation in R&D decrease of 8% to $7.7M (expense). |
PTCTのテクニカル分析
PTCTのニュース
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT 2023/06/03 18:10:00 Business Insider Markets
[DATELINE]Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors are advised to contact Robert S.
3 High-Potential Small-Cap Stocks for Investors With Strong Stomachs 2023/05/31 19:45:19 InvestorPlace
When looking for big winners in the stock market, smaller is better. A gigantic firm like Apple (NASDAQ: AAPL ) can realistically only go up so much in a given time period. Simply put, iPhone sales aren’t going to triple anytime soon. High-risk high-reward small-cap stocks, on the other hand, can have tremendous near-term upside if things go correctly for the company. To be clear, these are the top small-cap stocks for people with strong stomachs. Volatility will be a given. And there is a real risk of failure if these companies aren’t able to deliver on their business models. But, for investors willing to endure some risk, these high return small-cap stocks could be multi-baggers over the next few years. As such, let’s take a look at these three promising companies today. LLAP Terran Orbital $1.18 PACW PacWest Bancorp $6.52 CLPT ClearPoint Neuro $7.70 Terran Orbital (LLAP) Source: andrey_l/Shutterstock Terran Orbital (NYSE: LLAP ) is a high-risk high-reward small-cap stock focused on the space industry.
PTC Therapeutics: Rare Disease Specialist''s Stock In Danger Of Slipping Further 2023/05/25 16:40:30 Seeking Alpha
PTC Therapeutics still sees losses despite its commercial DMD franchise. Read why I think PTC''s business looks overvalued.
UBS maintains PTC Therapeutics at ''neutral'' with a price target of $52.00 2023/05/25 12:56:43 Investing.com
https://www.investing.com/news/pro/ptc-therape-receives-investment-bank-analyst-rating-update-3091062
Reata adds 21% as PTC’s Friedreich''s ataxia drug fails Phase 3 trial 2023/05/24 18:26:51 Seeking Alpha
Reata Pharmaceuticals (RETA) and PTC Therapeutics (PTCT) moved sideways Wednesday after the latter''s Friedreich''s ataxia ((FA)) vatiquinone failed. Read more here.
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of PTC Therapeutics, Inc. (PTCT) and Encourages Long-Term PTCT Investors to Contact the Firm 2023/02/27 15:00:00 GlobeNewswire
PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating PTC Therapeutics, Inc. (NASDAQ: PTCT) on behalf of the company’s long-term investors.
Investing in PTC Therapeutics Inc. (PTCT) might be a great opportunity, but the stock is a bit undervalued 2023/02/24 12:08:00 US Post News
PTC Therapeutics Inc. (NASDAQ:PTCT) closed Thursday at $43.52 per share, down from $44.23 a day earlier. While PTC Therapeutics Inc. has underperformed by -1.61%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PTCT rose by 13.19%, with highs and lows ranging from $55.58 to $25.01, whereas […]
Looking Into PTC Therapeutics''s Return On Capital Employed 2023/02/22 14:48:08 Benzinga
PTC Therapeutics (NASDAQ: PTCT ) brought in sales totaling $167.41 million during Q4 according to data provided by Benzinga Pro . However, earnings decreased 56.33%, resulting in a loss of $170.89 million. In Q3, PTC Therapeutics brought in $217.13 million in sales but lost $109.31 million in earnings. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and … Full story available on Benzinga.com
PTC Therapeutics PT Lowered to $57 at JPMorgan 2023/02/22 09:01:01 Investing.com
https://www.investing.com/news/pro/ptc-therapeutics-pt-lowered-to-57-at-jpmorgan-432SI-3009958
PTC Therapeutics, Inc. (PTCT) Q4 2022 Earnings Call Transcript 2023/02/22 03:35:24 Seeking Alpha
PTC Therapeutics, Inc. (NASDAQ:NASDAQ:PTCT) Q4 2022 Earnings Conference Call February 21, 2023 4:30 PM ETCompany ParticipantsKylie O''Keefe - Chief Commercial OfficerStuart Peltz - Chief…
PTC Therapeutics''s Return On Capital Employed Overview 2022/11/02 14:19:10 Benzinga
According to Benzinga Pro data, during Q3, PTC Therapeutics (NASDAQ: PTCT ) posted sales of $217.13 million. Earnings were up 28.12%, but PTC Therapeutics still reported an overall loss of $109.31 million. PTC Therapeutics collected $165.53 million in revenue during Q2, but reported earnings showed a $152.09 million loss. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a … Full story available on Benzinga.com
What To Expect As PTC Therapeutics Inc. (NASDAQ: PTCT) Delivers An 8.89% Loss In 6 Months 2022/10/29 20:00:00 Marketing Sentinel
During the last session, PTC Therapeutics Inc. (NASDAQ:PTCT)’s traded shares were 1.89 million, with the beta value of the company hitting 0.56. At the end of the trading day, the stock’s price was $38.47, reflecting an intraday loss of -13.73% or -$6.12. The 52-week high for the PTCT share is $55.58, that puts it down … What To Expect As PTC Therapeutics Inc. (NASDAQ: PTCT) Delivers An 8.89% Loss In 6 Months Read More »
PTC Therapeutics Grabs Up to $1 Billion, but There''s a Catch 2022/10/28 20:03:33 The Street
The drug developer''s financing deal with Blackstone has several strings attached.
PTC Therapeutics Gets $1B Funding From Blackstone, Shares Fall 2022/10/28 15:08:17 Benzinga
PTC Therapeutics Inc (NASDAQ: PTCT ) entered into a strategic financing collaboration with Blackstone Inc (NYSE: BX ). As part of the collaboration, Blackstone Life Sciences and Blackstone Credit will provide PTC with an initial $500 million commitment, including $350 million in low-cost, low-dilution capital. "This strategic financing will support the … Full story available on Benzinga.com
PTC Therapeutics Inc. (PTCT) can beat the pack with these strategies 2022/10/28 11:40:00 US Post News
In Thursday’s session, PTC Therapeutics Inc. (NASDAQ:PTCT) marked $44.59 per share, down from $45.65 in the previous session. While PTC Therapeutics Inc. has underperformed by -2.32%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PTCT rose by 25.78%, with highs and lows ranging from $55.58 to […]